Solution provided
Supplier identity
General description

The start-up project Xenothera SAS aims to bring to clinic xenogeneic cell and tissue therapies for curing diabetes mellitus type 1, corneal blindness and Parkinson disease. Xenothera SAS aims to become a leader in Europe in the market of xenogeneic therapies development, based on the breading of SPF source pig.

Type of Supplier
Biotechnology Company - Therapeutics
Regions of Pays de la Loire, Centre and Poitou-Charentes, FR
Regional access broker
  • Grégory Bauer, Atlanpole Biotherapies
Activity description
The 3 top equipments available

The start-up will set up as a biotechnological platform providing first SPF pigs designed for medical use and then GMP xenogeneic tissues and cells for clinical use. The originalty of the offer will first be based on the ability to bread a SPF pig herd in a confined biosafety facility, with a high health and controlled sanitarian status.

The value chain of Xenothera will also be based at the further stages of the development process for moving toward a clinical use. from the SPF pig herd to GMP tissue and cell production to the preclinical and clinical validation of the GMP xenogenenic products (up to phase I/II).

It is expected at the end of the process to sell patents or licenses pertaining to the process production or directly GMP pig tissue or cells for clinical use.


Know-how, expertise available

Xenothera SAS project is led by David Riochet.

Main Xenothera SAS potential founders and scientific advisors involved are:

  • Jean-Marie Bach (Oniris/INRA 707),.
  • Gilles Blancho (Nantes University Hospital/ITUN-INSERM 1064),
  • Emmanuele Cozzi (CORIT, Padova University Hospital),
  • Pascal Mermillod (INRA Nouzilly),
  • Gilles Salvat (ANSES Ploufragan),
  • Jean-Paul Soulillou (Nantes University/ITUN-INSERM 1064)
  • and Bertrand Vabres (Nantes University Hospital).
Training and Staff possibilities
Contact information
Phone number
+33 (0)2 40 08 78 99
30 boulevard Jean Monnet
44093  NANTES